AIC
MRNA icon

Argus Investors Counsel’s Moderna MRNA Stock Holding History

Argus Investors Counsel’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,103
Closed -$527K – 103
2023
Q3 		$527K Buy
5,103
+259
+5% +$28.9K 0.38% 74
2023
Q2 		$589K Buy
4,844
+50
+1% +$6.67K 0.41% 73
2023
Q1 		$736K Buy
+4,794
New +$791K 0.56% 69

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Argus Investors Counsel's MRNA Position: Q4 2023 in Review

Argus Investors Counsel sold out of Moderna (MRNA) in Q4 2023, closing a stake of 5,103 shares — an estimated $527K sold.

Argus Investors Counsel first reported a position in MRNA in Q1 2023 and held it in 3 quarters. The position peaked at $736K in Q1 2023. 885 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Argus Investors Counsel reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Argus Investors Counsel sold 5,103 Moderna shares in Q4 2023, an estimated $527K.
  • Argus Investors Counsel first reported a position in Moderna in Q1 2023 and held it in 3 quarters.
  • Argus Investors Counsel's Moderna position peaked at $736K in Q1 2023.
  • 885 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Argus Investors Counsel's 13F filing for Q4 2023, filed 22 Jan 2024.